Search results
Qsemble Capital Management LP Purchases Shares of 239 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
ETF DAILY NEWS· 1 day agoQsemble Capital Management LP acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) during the 4th quarter, according ...
...s How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 10 Years - ...
Benzinga· 20 hours agoRegeneron Pharmaceuticals REGN has outperformed the market over the past 10 years by 2.01% on an annualized basis producing an average annual return of ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Merit Financial Group LLC
ETF DAILY NEWS· 6 days agoMerit Financial Group LLC lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 53.7% in the fourth quarter, ...
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) large institutional owners must be happy as stock...
Simply Wall St. via Yahoo Finance· 5 days agoKey Insights Institutions' substantial holdings in Regeneron Pharmaceuticals implies that they have...
Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Younger CRSwNP Group
Morningstar· 2 days agoRegeneron Pharmaceuticals and Sanofi have won Food and Drug Administration priority review of their application seeking expanded approval of their blockbuster ...
... for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) - ...
Benzinga· 2 days agoRegeneron Pharmaceuticals, Inc. REGN and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental ...
Regeneron shares rise on Evercore ISI Outperform rating By Investing.com
Investing.com· 2 days agoOn Monday, Evercore ISI initiated coverage on Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc....
Regeneron’s gene therapy triumphs twice, restoring hearing in children
Clinical Trials Arena via Yahoo Finance· 6 days agoThe two children with rare genetic otoferlin hearing loss enrolled in the Phase I/II trial for...
Pipeline Moves: Phase III completion for Corcept’s relaorilant
Clinical Trials Arena via Yahoo Finance· 2 days agoPhase II trial of Regeneron‘s mibavademab completes Regeneron Pharmaceuticals’s mibavademab saw its...
FDA considers Dupixent for adolescent sinusitis treatment By Investing.com
Investing.com· 2 days agoThe U.S. Food and Drug Administration (FDA) has granted Priority Review for the supplemental...